Remus PharmaceuticalsNSE:REMUS +0.24%54 Days Payable is 46.73 as of Mar. 2026, which is 45% below its 10-year median of 85.29. GuruFocus rates NSE:REMUS with a GF Score™ of 54/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 115 Medical Distribution companies, Remus Pharmaceuticals ranks worse than 81.74% on this metric.
Remus Pharmaceuticals Days Payable Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:REMUS vs MCK, CAH, COR: Days Payable Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Remus Pharmaceuticals's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Remus Pharmaceuticals (NSE:REMUS) has a Days Payable of 46.73 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Remus Pharmaceuticals and its competitors. This is 45% below median its historical median of 85.29. Over the past decade, Remus Pharmaceuticals' Days Payable has ranged from 36.23 to 146.00. According to the industry distribution chart, Remus Pharmaceuticals ranks #94 out of 115 companies in the Medical Distribution industry, placing it in the top 81.7%.
Is Remus Pharmaceuticals' Days Payable too high?
Remus Pharmaceuticals' current Days Payable of 46.73 is 45% below median its 10-year median of 85.29. Over the past 10 years, this metric has ranged from a low of 36.23 to a high of 146.00. The Medical Distribution industry median Days Payable is 79.81. Remus Pharmaceuticals' value of 46.73 is 41.4% below this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #94 out of 115 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Remus Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Days Payable compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #94 out of 115 companies for Days Payable. This places Remus Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 79.81. Remus Pharmaceuticals' value of 46.73 is 41.4% below this benchmark. Historically, Remus Pharmaceuticals' own Days Payable has ranged from 36.23 to 146.00 over the past decade. While the company's 10-year median is 85.29 vs. the industry median of 79.81, Remus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 79.81, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current Days Payable of 46.73 is 41.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median Days Payable is 79.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current Days Payable is 46.73, which is 45% below median its own 10-year median of 85.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹746.05 — trading 64% below its estimated fair value. The current Days Payable is 46.73, which is 45% below median its 10-year median of 85.29 and 41.4% below the Medical Distribution industry median of 79.81. Remus Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Days Payable is 46.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹746.05 is trading 64% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
Days Payable: 46.73 (45% below median its 10-year median of 85.29)
GF Value™: ₹2,071.36 vs. price of ₹746.05 (64% below fair value)
Industry Position: 41.4% below the Medical Distribution median (#94 of 115)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
54GF Score
Get the complete analysis for NSE:REMUS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
